Edunn Biotechnology

Edunn Biotechnology is a biotechnology company dedicated to developing oligonucleotide drugs for the treatment of central nervous system diseases. The company has developed a drug, ol-1, for treating cholinergic symptoms of Alzheimer's disease and Down syndrome. Its ol-202 is used for treating stroke and traumatic brain injury. The company was founded in 2005 and is headquartered in St. Louis, Missouri.